PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Customers can have the chance to win highly desirable properties ranging from £350,000 to £650,000. After purchasing a £5 ticket and answering one multiple-choice question correctly, customers will be entered into a draw to win a property. Raffle House also donate 5% of their ticket sales revenue to a homelessness charity chosen by their customers.
days to go:
Expired
investment:
£269,419
Value Chain Lab streamlines supply chains by removing logistics waste.
http://www.valuechainlab.com/
days to go:
Expired
investment:
£330,874
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
Cyclr is a cloud-based software that allows the user to connect the apps that they already run their business on. This makes it simple to synchronise data with another system.
days to go:
Expired
investment:
£100,490
Lifetise generates proprietary consumer data via its portal to boost the Artificial Intelligence (AI) based decision-making process within banks and insurers and increase their product sales. Lifetise asserts that its portal helps financial institutions acquire and fulfil the needs of high-value customers at a lower cost to the organisation. It is in negotiations with three retail banks and is an Accenture Fintech Lab alumni. The company was named as one of the most influential financial technology entities of 2020 by The Financial Technologist magazine and selected for the Mayor of London's 'Business Growth Programme' under the 'Most high potential startups' category in 2021. Lifetise will use 58% of the investment in product development and engineering to scale its technology platform, 31% on sales and marketing, and 11% on operations.
days to go:
Expired
investment:
£369,407
Loanpad is a financial technology entity that provides a user-friendly, lower-risk platform for investors to earn inflation-busting interest through shared short-term property loans. It argues that its portal shields customers from much of the risk of peer-to-peer (P2P) lending by partnering with established property lenders, who take on both higher risk and return. Investors can invest through Loanpad's Classic and/or Premium accounts (both ISA eligible). The Classic account pays 3% and allows daily withdrawals, while the Premium account pays 4% and requires a 60-day notice for withdrawals. Loanpad has over £22 million in funds under management, onboarded over 2,600 registered investors, and witnessed over 150% growth in loans through 2020. It is authorised by the Financial Conduct Authority (FCA). It will use the investment to boost marketing, further develop software capabilities, increase the size of its Interest Cover Fund (ICF), and invest in general working capital.
days to go:
Expired
investment:
£423,060
